AXL and non-small cell lung carcinoma: αvβ3 integrin promoted erlotinib resistance by upregulating AXL through the YAP pathway in erlotinib-resistant NSCLC cells, and the resistance to erlotinib was significantly inhibited by the AXL inhibitor R428 (bemcentinib).